Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Depression-Pipeline Review, H1 2015

Depression-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Depression-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Depression-Pipeline Review, H1 2015', provides an overview of the Depression's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Depression and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Depression

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Depression and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Depression pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Depression

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Depression Overview 8

Therapeutics Development 9

Depression-Therapeutics under Development by Companies 11

Depression-Therapeutics under Investigation by Universities/Institutes 19

Depression-Pipeline Products Glance 21

Depression-Products under Development by Companies 25

Depression-Products under Investigation by Universities/Institutes 36

Depression-Companies Involved in Therapeutics Development 38

Depression-Therapeutics Assessment 123

Drug Profiles 140

Depression-Recent Pipeline Updates 345

Depression-Dormant Projects 396

Depression-Discontinued Products 416

Depression-Product Development Milestones 423

Appendix 436

List of Tables

Number of Products under Development for Depression, H1 2015 27

Number of Products under Development for Depression-Comparative Analysis, H1 2015 28

Number of Products under Development by Companies, H1 2015 30

Number of Products under Development by Companies, H1 2015 (Contd..1) 31

Number of Products under Development by Companies, H1 2015 (Contd..2) 32

Number of Products under Development by Companies, H1 2015 (Contd..3) 33

Number of Products under Development by Companies, H1 2015 (Contd..4) 34

Number of Products under Development by Companies, H1 2015 (Contd..5) 35

Number of Products under Development by Companies, H1 2015 (Contd..6) 36

Number of Products under Investigation by Universities/Institutes, H1 2015 38

Comparative Analysis by Late Stage Development, H1 2015 39

Comparative Analysis by Clinical Stage Development, H1 2015 40

Comparative Analysis by Early Stage Development, H1 2015 41

Comparative Analysis by Unknown Stage Development, H1 2015 42

Products under Development by Companies, H1 2015 43

Products under Development by Companies, H1 2015 (Contd..1) 44

Products under Development by Companies, H1 2015 (Contd..2) 45

Products under Development by Companies, H1 2015 (Contd..3) 46

Products under Development by Companies, H1 2015 (Contd..4) 47

Products under Development by Companies, H1 2015 (Contd..5) 48

Products under Development by Companies, H1 2015 (Contd..6) 49

Products under Development by Companies, H1 2015 (Contd..7) 50

Products under Development by Companies, H1 2015 (Contd..8) 51

Products under Development by Companies, H1 2015 (Contd..9) 52

Products under Development by Companies, H1 2015 (Contd..10) 53

Products under Investigation by Universities/Institutes, H1 2015 54

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 55

Depression-Pipeline by AB Science, H1 2015 56

Depression-Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 57

Depression-Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 58

Depression-Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 59

Depression-Pipeline by Adamed Sp. z o.o., H1 2015 60

Depression-Pipeline by Addex Therapeutics Ltd, H1 2015 61

Depression-Pipeline by Alkermes Plc, H1 2015 62

Depression-Pipeline by Allergan, Inc., H1 2015 63

Depression-Pipeline by Anavex Life Sciences Corp., H1 2015 64

Depression-Pipeline by Angelini Group, H1 2015 65

Depression-Pipeline by Angita B.V., H1 2015 66

Depression-Pipeline by Ascendis Pharma A/S, H1 2015 67

Depression-Pipeline by AstraZeneca PLC, H1 2015 68

Depression-Pipeline by Avanir Pharmaceuticals, Inc., H1 2015 69

Depression-Pipeline by Azevan Pharmaceuticals, Inc., H1 2015 70

Depression-Pipeline by Beech Tree Labs, Inc., H1 2015 71

Depression-Pipeline by BioCrea GmbH, H1 2015 72

Depression-Pipeline by Bionomics Limited, H1 2015 73

Depression-Pipeline by Boehringer Ingelheim GmbH, H1 2015 74

Depression-Pipeline by Bristol-Myers Squibb Company, H1 2015 75

Depression-Pipeline by Calico LLC, H1 2015 76

Depression-Pipeline by Cerecor Inc., H1 2015 77

Depression-Pipeline by Clera Inc., H1 2015 78

Depression-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 79

Depression-Pipeline by Convergence Pharmaceuticals Ltd., H1 2015 80

Depression-Pipeline by D-Pharm Ltd., H1 2015 81

Depression-Pipeline by Delpor, Inc., H1 2015 82

Depression-Pipeline by Domain Therapeutics SA, H1 2015 83

Depression-Pipeline by e-Therapeutics plc, H1 2015 84

Depression-Pipeline by Edgemont Pharmaceuticals, LLC, H1 2015 85

Depression-Pipeline by Eisai Co., Ltd., H1 2015 86

Depression-Pipeline by Eli Lilly and Company, H1 2015 87

Depression-Pipeline by Euthymics Bioscience, Inc., H1 2015 88

Depression-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 89

Depression-Pipeline by GlaxoSmithKline plc, H1 2015 90

Depression-Pipeline by GliaCure Inc., H1 2015 91

Depression-Pipeline by H. Lundbeck A/S, H1 2015 92

Depression-Pipeline by Heptares Therapeutics Ltd., H1 2015 93

Depression-Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H1 2015 94

Depression-Pipeline by Intas Pharmaceuticals Ltd., H1 2015 95

Depression-Pipeline by Intra-Cellular Therapies, Inc., H1 2015 96

Depression-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 97

Depression-Pipeline by Johnson & Johnson, H1 2015 98

Depression-Pipeline by KemPharm, Inc., H1 2015 99

Depression-Pipeline by KunWha Pharmaceutical Co., Ltd., H1 2015 100

Depression-Pipeline by Lead Discovery Center GmbH, H1 2015 101

Depression-Pipeline by Luye Pharma Group Ltd., H1 2015 102

Depression-Pipeline by M et P Pharma AG, H1 2015 103

Depression-Pipeline by Mapreg S.A.S., H1 2015 104

Depression-Pipeline by MarcoPolo Pharmaceuticals SA, H1 2015 105

Depression-Pipeline by Meta-IQ ApS, H1 2015 106

Depression-Pipeline by Methylation Sciences Inc., H1 2015 107

Depression-Pipeline by MI.TO. Technology S.r.L., H1 2015 108

Depression-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 109

Depression-Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 110

Depression-Pipeline by Naurex, Inc., H1 2015 111

Depression-Pipeline by Nektar Therapeutics, H1 2015 112

Depression-Pipeline by NeRRe Therapeutics Ltd, H1 2015 113

Depression-Pipeline by Neuralstem, Inc., H1 2015 114

Depression-Pipeline by NeuroNascent, Inc., H1 2015 115

Depression-Pipeline by Newron Pharmaceuticals S.p.A., H1 2015 116

Depression-Pipeline by nLife Therapeutics, S.L., H1 2015 117

Depression-Pipeline by Omeros Corporation, H1 2015 118

Depression-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 119

Depression-Pipeline by Pfizer Inc., H1 2015 120

Depression-Pipeline by Pherin Pharmaceuticals, Inc., H1 2015 121

Depression-Pipeline by PsychoGenics, Inc., H1 2015 122

Depression-Pipeline by Reviva Pharmaceuticals Inc., H1 2015 123

Depression-Pipeline by Richter Gedeon Nyrt., H1 2015 124

Depression-Pipeline by Saniona AB, H1 2015 125

Depression-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 126

Depression-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 127

Depression-Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 128

Depression-Pipeline by Supernus Pharmaceuticals, Inc., H1 2015 129

Depression-Pipeline by Suven Life Sciences Ltd., H1 2015 130

Depression-Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 131

Depression-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 132

Depression-Pipeline by Tesaro, Inc., H1 2015 133

Depression-Pipeline by Tetra Discovery Partners LLC, H1 2015 134

Depression-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 135

Depression-Pipeline by Trevena, Inc., H1 2015 136

Depression-Pipeline by VistaGen Therapeutics , Inc., H1 2015 137

Depression-Pipeline by Zhejiang Huahai Pharmaceutical Co., Ltd., H1 2015 138

Depression-Pipeline by Zogenix, Inc., H1 2015 139

Depression-Pipeline by Zysis Limited, H1 2015 140

Assessment by Monotherapy Products, H1 2015 141

Assessment by Combination Products, H1 2015 142

Number of Products by Stage and Target, H1 2015 144

Number of Products by Stage and Mechanism of Action, H1 2015 150

Number of Products by Stage and Route of Administration, H1 2015 155

Number of Products by Stage and Molecule Type, H1 2015 157

Depression Therapeutics-Recent Pipeline Updates, H1 2015 363

Depression-Dormant Projects, H1 2015 414

Depression-Dormant Projects (Contd..1), H1 2015 415

Depression-Dormant Projects (Contd..2), H1 2015 416

Depression-Dormant Projects (Contd..3), H1 2015 417

Depression-Dormant Projects (Contd..4), H1 2015 418

Depression-Dormant Projects (Contd..5), H1 2015 419

Depression-Dormant Projects (Contd..6), H1 2015 420

Depression-Dormant Projects (Contd..7), H1 2015 421

Depression-Dormant Projects (Contd..8), H1 2015 422

Depression-Dormant Projects (Contd..9), H1 2015 423

Depression-Dormant Projects (Contd..10), H1 2015 424

Depression-Dormant Projects (Contd..11), H1 2015 425

Depression-Dormant Projects (Contd..12), H1 2015 426

Depression-Dormant Projects (Contd..13), H1 2015 427

Depression-Dormant Projects (Contd..14), H1 2015 428

Depression-Dormant Projects (Contd..15), H1 2015 429

Depression-Dormant Projects (Contd..16), H1 2015 430

Depression-Dormant Projects (Contd..17), H1 2015 431

Depression-Dormant Projects (Contd..18), H1 2015 432

Depression-Dormant Projects (Contd..19), H1 2015 433

Depression-Discontinued Products, H1 2015 434

Depression-Discontinued Products (Contd..1), H1 2015 435

Depression-Discontinued Products (Contd..2), H1 2015 436

Depression-Discontinued Products (Contd..3), H1 2015 437

Depression-Discontinued Products (Contd..4), H1 2015 438

Depression-Discontinued Products (Contd..5), H1 2015 439

Depression-Discontinued Products (Contd..6), H1 2015 440

List of Figures

Number of Products under Development for Depression, H1 2015 27

Number of Products under Development for Depression-Comparative Analysis, H1 2015 28

Number of Products under Development by Companies, H1 2015 29

Number of Products under Investigation by Universities/Institutes, H1 2015 37

Comparative Analysis by Late Stage Development, H1 2015 39

Comparative Analysis by Clinical Stage Development, H1 2015 40

Comparative Analysis by Early Stage Products, H1 2015 41

Assessment by Monotherapy Products, H1 2015 141

Assessment by Combination Products, H1 2015 142

Number of Products by Top 10 Targets, H1 2015 143

Number of Products by Stage and Top 10 Targets, H1 2015 143

Number of Products by Top 10 Mechanism of Actions, H1 2015 149

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 149

Number of Products by Top 10 Routes of Administration, H1 2015 154

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 154

Number of Products by Top 10 Molecule Types, H1 2015 156

Number of Products by Stage and Top 10 Molecule Types, H1 2015 156

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

Acetylon Pharmaceuticals, Inc.

Ache Laboratorios Farmaceuticos S/A

Adamas Pharmaceuticals, Inc.

Adamed Sp. z o.o.

Addex Therapeutics Ltd

Alkermes Plc

Allergan, Inc.

Anavex Life Sciences Corp.

Angelini Group

Angita B.V.

Ascendis Pharma A/S

AstraZeneca PLC

Avanir Pharmaceuticals, Inc.

Azevan Pharmaceuticals, Inc.

Beech Tree Labs, Inc.

BioCrea GmbH

Bionomics Limited

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Calico LLC

Cerecor Inc.

Clera Inc.

Concert Pharmaceuticals, Inc.

Convergence Pharmaceuticals Ltd.

D-Pharm Ltd.

Delpor, Inc.

Domain Therapeutics SA

e-Therapeutics plc

Edgemont Pharmaceuticals, LLC

Eisai Co., Ltd.

Eli Lilly and Company

Euthymics Bioscience, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

GliaCure Inc.

H. Lundbeck A/S

Heptares Therapeutics Ltd.

HolsboerMaschmeyer NeuroChemie GmbH

Intas Pharmaceuticals Ltd.

Intra-Cellular Therapies, Inc.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Johnson & Johnson

KemPharm, Inc.

KunWha Pharmaceutical Co., Ltd.

Lead Discovery Center GmbH

Luye Pharma Group Ltd.

M et P Pharma AG

Mapreg S.A.S.

MarcoPolo Pharmaceuticals SA

Meta-IQ ApS

Methylation Sciences Inc.

MI.TO. Technology S.r.L.

Mitsubishi Tanabe Pharma Corporation

Mnemosyne Pharmaceuticals, Inc.

Naurex, Inc.

Nektar Therapeutics

NeRRe Therapeutics Ltd

Neuralstem, Inc.

NeuroNascent, Inc.

Newron Pharmaceuticals S.p.A.

nLife Therapeutics, S.L.

Omeros Corporation

Otsuka Holdings Co., Ltd.

Pfizer Inc.

Pherin Pharmaceuticals, Inc.

PsychoGenics, Inc.

Reviva Pharmaceuticals Inc.

Richter Gedeon Nyrt.

Saniona AB

SK Biopharmaceuticals Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc.

Supernus Pharmaceuticals, Inc.

Suven Life Sciences Ltd.

Taisho Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited

Tesaro, Inc.

Tetra Discovery Partners LLC

Teva Pharmaceutical Industries Limited

Trevena, Inc.

VistaGen Therapeutics , Inc.

Zhejiang Huahai Pharmaceutical Co., Ltd.

Zogenix, Inc.

Zysis Limited

Depression Therapeutic Products under Development, Key Players in Depression Therapeutics, Depression Pipeline Overview, Depression Pipeline, Depression Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com